MAPK Signaling: Mitogens

No Pathway Network information available for MAPK Signaling: Mitogens

Pathways in the MAPK Signaling: Mitogens SuperPath

#	Name	Source	Genes
1	MAPK Signaling: Mitogens	R&D Systems	AKT1S1 ARAF BRAF CAD CCND1 CCND2 CCND3 CDK4 DEPTOR E2F1 E2F2 E2F4 EGFR EIF4A1 EIF4B EIF4E EIF4EBP1 EIF4G1 ERBB2 ERBB3 ERBB4 FGFR1 FGFR2 FGFR3 FGFR4 FGFRL1 FLT1 FLT4 GRB2 IGF1R IGF2R IL17RD INSR INSRR KDR KRAS KSR1 LAMTOR2 LAMTOR3 MAP2K1 MAP2K2 MAPK1 MAPK3 MET MFRP MLST8 MRAS MTOR MYC NTRK1 NTRK2 NTRK3 PDCD4 PDGFRA PDGFRB PHB1 PHB2 PLCG1 PLCG2 RAF1 RASGRP1 RB1 RHEB RPL17 RPS6 RPS6KA2 RPS6KA6 RPS6KB1 RPS6KB2 RPTOR SOS2 SRC TEK TIE1 TOB1 TSC1 TSC2 UBTF (see all 78) (see less)
2	Akt Signaling Pathway	R&D Systems	AKT1 AKT1S1 AKT2 AKT3 BAD BCL2L1 BCL2L11 BECN1 CASP3 CDK2 CDK4 CDKN1A CDKN1B DEPTOR E2F1 E2F2 E2F4 EGFR EIF4B EIF4E EIF4EBP1 EIF4G1 ERBB2 ERBB3 ERBB4 FGFR1 FGFR2 FGFR3 FGFR4 FLT1 FLT4 FOXO1 FOXO3 GAB2 GAB3 GRB2 GRB7 GSK3A GSK3B IGF1R IGF2R INSR INSRR KDR KRAS MDM2 MET MLST8 MTOR MYC NTRK1 NTRK2 NTRK3 PDCD4 PDGFRA PDGFRB PDPK1 PIK3CB PIK3CD PIK3CG PIK3R1 PIK3R2 PIK3R4 PRR5 PTEN RHEB RICTOR RPS6KB1 RPS6KB2 RPTOR TEK TIE1 TP53 TSC1 TSC2 (see all 75) (see less)

Ordered by rank within the SuperPath, via the multiplicity of each gene in the constituent pathways

#	Symbol	Description	Category	# Related Pathways
1	EGFR	Epidermal Growth Factor Receptor	Protein Coding	2
2	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	2
3	ERBB3	Erb-B2 Receptor Tyrosine Kinase 3	Protein Coding	2
4	ERBB4	Erb-B2 Receptor Tyrosine Kinase 4	Protein Coding	2
5	FGFR1	Fibroblast Growth Factor Receptor 1	Protein Coding	2
6	FGFR2	Fibroblast Growth Factor Receptor 2	Protein Coding	2
7	FGFR3	Fibroblast Growth Factor Receptor 3	Protein Coding	2
8	FGFR4	Fibroblast Growth Factor Receptor 4	Protein Coding	2
9	MET	MET Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	2
10	IGF1R	Insulin Like Growth Factor 1 Receptor	Protein Coding	2
11	IGF2R	Insulin Like Growth Factor 2 Receptor	Protein Coding	2
12	INSR	Insulin Receptor	Protein Coding	2
13	INSRR	Insulin Receptor Related Receptor	Protein Coding	2
14	PDGFRA	Platelet Derived Growth Factor Receptor Alpha	Protein Coding	2
15	PDGFRB	Platelet Derived Growth Factor Receptor Beta	Protein Coding	2
16	TIE1	Tyrosine Kinase With Immunoglobulin Like And EGF Like Domains 1	Protein Coding	2
17	TEK	TEK Receptor Tyrosine Kinase	Protein Coding	2
18	NTRK1	Neurotrophic Receptor Tyrosine Kinase 1	Protein Coding	2
19	NTRK2	Neurotrophic Receptor Tyrosine Kinase 2	Protein Coding	2
20	NTRK3	Neurotrophic Receptor Tyrosine Kinase 3	Protein Coding	2
21	FLT1	Fms Related Receptor Tyrosine Kinase 1	Protein Coding	2
22	KDR	Kinase Insert Domain Receptor	Protein Coding	2
23	FLT4	Fms Related Receptor Tyrosine Kinase 4	Protein Coding	2
24	GRB2	Growth Factor Receptor Bound Protein 2	Protein Coding	2
25	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	2
26	TSC1	TSC Complex Subunit 1	Protein Coding	2
27	TSC2	TSC Complex Subunit 2	Protein Coding	2
28	RHEB	Ras Homolog, MTORC1 Binding	Protein Coding	2
29	MTOR	Mechanistic Target Of Rapamycin Kinase	Protein Coding	2
30	RPTOR	Regulatory Associated Protein Of MTOR Complex 1	Protein Coding	2
31	MLST8	MTOR Associated Protein MLST8	Protein Coding	2
32	AKT1S1	AKT1 Substrate 1	Protein Coding	2
33	DEPTOR	DEP Domain Containing MTOR Interacting Protein	Protein Coding	2
34	EIF4EBP1	Eukaryotic Translation Initiation Factor 4E Binding Protein 1	Protein Coding	2
35	RPS6KB1	Ribosomal Protein S6 Kinase B1	Protein Coding	2
36	RPS6KB2	Ribosomal Protein S6 Kinase B2	Protein Coding	2
37	PDCD4	Programmed Cell Death 4	Protein Coding	2
38	EIF4B	Eukaryotic Translation Initiation Factor 4B	Protein Coding	2
39	EIF4G1	Eukaryotic Translation Initiation Factor 4 Gamma 1	Protein Coding	2
40	EIF4E	Eukaryotic Translation Initiation Factor 4E	Protein Coding	2
41	CDK4	Cyclin Dependent Kinase 4	Protein Coding	2
42	E2F1	E2F Transcription Factor 1	Protein Coding	2
43	E2F2	E2F Transcription Factor 2	Protein Coding	2
44	E2F4	E2F Transcription Factor 4	Protein Coding	2
45	MYC	MYC Proto-Oncogene, BHLH Transcription Factor	Protein Coding	2
46	FGFRL1	Fibroblast Growth Factor Receptor Like 1	Protein Coding	1
47	SOS2	SOS Ras/Rho Guanine Nucleotide Exchange Factor 2	Protein Coding	1
48	MRAS	Muscle RAS Oncogene Homolog	Protein Coding	1
49	PHB1	Prohibitin 1	Protein Coding	1
50	PHB2	Prohibitin 2	Protein Coding	1
51	RAF1	Raf-1 Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	1
52	ARAF	A-Raf Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	1
53	BRAF	B-Raf Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	1
54	KSR1	Kinase Suppressor Of Ras 1	Protein Coding	1
55	MAPK3	Mitogen-Activated Protein Kinase 3	Protein Coding	1
56	MAPK1	Mitogen-Activated Protein Kinase 1	Protein Coding	1
57	MFRP	Membrane Frizzled-Related Protein	Protein Coding	1
58	MAP2K2	Mitogen-Activated Protein Kinase Kinase 2	Protein Coding	1
59	SRC	SRC Proto-Oncogene, Non-Receptor Tyrosine Kinase	Protein Coding	1
60	PLCG1	Phospholipase C Gamma 1	Protein Coding	1
61	PLCG2	Phospholipase C Gamma 2	Protein Coding	1
62	RASGRP1	RAS Guanyl Releasing Protein 1	Protein Coding	1
63	MAP2K1	Mitogen-Activated Protein Kinase Kinase 1	Protein Coding	1
64	IL17RD	Interleukin 17 Receptor D	Protein Coding	1
65	RPS6KA2	Ribosomal Protein S6 Kinase A2	Protein Coding	1
66	RPS6KA6	Ribosomal Protein S6 Kinase A6	Protein Coding	1
67	EIF4A1	Eukaryotic Translation Initiation Factor 4A1	Protein Coding	1
68	LAMTOR3	Late Endosomal/Lysosomal Adaptor, MAPK And MTOR Activator 3	Protein Coding	1
69	LAMTOR2	Late Endosomal/Lysosomal Adaptor, MAPK And MTOR Activator 2	Protein Coding	1
70	TOB1	Transducer Of ERBB2, 1	Protein Coding	1
71	CCND1	Cyclin D1	Protein Coding	1
72	CCND2	Cyclin D2	Protein Coding	1
73	CCND3	Cyclin D3	Protein Coding	1
74	RB1	RB Transcriptional Corepressor 1	Protein Coding	1
75	CAD	Carbamoyl-Phosphate Synthetase 2, Aspartate Transcarbamylase, And Dihydroorotase	Protein Coding	1
76	UBTF	Upstream Binding Transcription Factor	Protein Coding	1
77	RPL17	Ribosomal Protein L17	Protein Coding	1
78	RPS6	Ribosomal Protein S6	Protein Coding	1
79	GAB2	GRB2 Associated Binding Protein 2	Protein Coding	1
80	GAB3	GRB2 Associated Binding Protein 3	Protein Coding	1
81	GRB7	Growth Factor Receptor Bound Protein 7	Protein Coding	1
82	PIK3CB	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta	Protein Coding	1
83	PIK3CG	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma	Protein Coding	1
84	PIK3CD	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta	Protein Coding	1
85	PIK3R1	Phosphoinositide-3-Kinase Regulatory Subunit 1	Protein Coding	1
86	PIK3R2	Phosphoinositide-3-Kinase Regulatory Subunit 2	Protein Coding	1
87	PDPK1	3-Phosphoinositide Dependent Protein Kinase 1	Protein Coding	1
88	RICTOR	RPTOR Independent Companion Of MTOR Complex 2	Protein Coding	1
89	PRR5	Proline Rich 5	Protein Coding	1
90	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	1
91	AKT2	AKT Serine/Threonine Kinase 2	Protein Coding	1
92	AKT3	AKT Serine/Threonine Kinase 3	Protein Coding	1
93	PTEN	Phosphatase And Tensin Homolog	Protein Coding	1
94	BECN1	Beclin 1	Protein Coding	1
95	PIK3R4	Phosphoinositide-3-Kinase Regulatory Subunit 4	Protein Coding	1
96	CDKN1B	Cyclin Dependent Kinase Inhibitor 1B	Protein Coding	1
97	MDM2	MDM2 Proto-Oncogene	Protein Coding	1
98	TP53	Tumor Protein P53	Protein Coding	1
99	GSK3A	Glycogen Synthase Kinase 3 Alpha	Protein Coding	1
100	GSK3B	Glycogen Synthase Kinase 3 Beta	Protein Coding	1
101	CDKN1A	Cyclin Dependent Kinase Inhibitor 1A	Protein Coding	1
102	CDK2	Cyclin Dependent Kinase 2	Protein Coding	1
103	FOXO1	Forkhead Box O1	Protein Coding	1
104	FOXO3	Forkhead Box O3	Protein Coding	1
105	BCL2L11	BCL2 Like 11	Protein Coding	1
106	CASP3	Caspase 3	Protein Coding	1
107	BCL2L1	BCL2 Like 1	Protein Coding	1
108	BAD	BCL2 Associated Agonist Of Cell Death	Protein Coding	1

Disorders associated with MAPK Signaling: Mitogens SuperPath

according to GeneCards Suite gene sharing

#	Disorder	Type	Genes	Score
1	Bladder cancer	Enrichment	CDKN1A, EGFR, ERBB2, ERBB3, FGFR3, KRAS, PTEN, TP53, TSC1	16.00
2	Ovarian cancer	Enrichment	AKT1, CDKN1B, EGFR, ERBB2, KRAS, MET, NTRK1, PDGFRA, PTEN, TP53, TSC2	16.00
3	Noonan syndrome 1	Enrichment	BRAF, KRAS, MAP2K1, MAP2K2, MRAS, RAF1, SOS2	10.10
4	Rasopathy	Enrichment	BRAF, KRAS, MAP2K1, MAP2K2, MRAS, RAF1, SOS2	10.05
5	Pilomyxoid astrocytoma	Enrichment	BRAF, FGFR1, KRAS, NTRK2, RAF1	9.85
6	Focal cortical dysplasia, type ii	Enrichment	MTOR, RHEB, TSC1, TSC2	9.06
7	Isolated focal cortical dysplasia type ii	Enrichment	MTOR, RHEB, TSC1, TSC2	9.06
8	Cardiofaciocutaneous syndrome 1	Enrichment	BRAF, KRAS, MAP2K1, MAP2K2	8.99
9	Cardiofaciocutaneous syndrome	Enrichment	BRAF, KRAS, MAP2K1, MAP2K2	8.99
10	Lung non-small cell carcinoma	Enrichment	BRAF, EGFR, ERBB2, KRAS, MAP2K1	8.60
11	Hemimegalencephaly	Enrichment	AKT3, MTOR, PTEN, RHEB	8.37
12	Lung cancer susceptibility 3	Enrichment	BRAF, EGFR, ERBB2, KRAS, RB1	7.97
13	Noonan syndrome and noonan-related syndrome	Enrichment	BRAF, KRAS, MAP2K1, MAP2K2, RAF1	7.80
14	Inherited cancer-predisposing syndrome	Enrichment	CDK4, CDKN1B, EGFR, MET, PDGFRA, PTEN, TP53, TSC1, TSC2	7.36
15	Gastric cancer	Enrichment	CDK4, ERBB2, FGFR2, KRAS, PTEN, TP53	6.92
16	Hamartoma	Enrichment	FGFR3, TSC1, TSC2	6.79
17	Colorectal cancer	Enrichment	AKT1, ERBB2, FGFR2, FGFR3, MET, PIK3R1, TP53	6.31
18	Glioma	Enrichment	FGFR2, NTRK3, PTEN	6.19
19	Lung cancer	Enrichment	BRAF, EGFR, ERBB2, KRAS, MET	6.01
20	Gliosarcoma	Enrichment	EGFR, FGFR1, FGFR3, TP53	5.83
21	Primary hypereosinophilic syndrome	Enrichment	FGFR1, PDGFRA, PDGFRB	5.79
22	Giant cell glioblastoma	Enrichment	EGFR, FGFR1, FGFR3, TP53	5.71
23	Breast adenocarcinoma	Enrichment	AKT1, KRAS, TP53	5.49
24	Lung squamous cell carcinoma	Enrichment	EGFR, FGFR3, KRAS	5.49
25	Arteriovenous malformations of the brain	Enrichment	BRAF, EGFR, IL17RD, KRAS	5.44
26	Squamous cell carcinoma, head and neck	Enrichment	EGFR, PTEN, TP53	5.25
27	Adult hepatocellular carcinoma	Enrichment	TP53, TSC1, TSC2	4.88
28	Differentiated thyroid carcinoma	Enrichment	BRAF, KRAS, NTRK1, NTRK3	4.67
29	Cervical cancer	Enrichment	FGFR3, TP53	4.52
30	Lymphangioleiomyomatosis	Enrichment	TSC1, TSC2	4.52
31	Pfeiffer syndrome	Enrichment	FGFR1, FGFR2	4.52
32	Jackson-weiss syndrome	Enrichment	FGFR1, FGFR2	4.52
33	Encephalocraniocutaneous lipomatosis	Enrichment	FGFR1, KRAS	4.52
34	Cervix carcinoma	Enrichment	FGFR3, TP53	4.52
35	Lip and oral cavity carcinoma	Enrichment	BRAF, EGFR, RB1	4.41
36	Nk-cell enteropathy	Enrichment	ERBB4, IGF1R, PIK3CB	4.35
37	Crouzon syndrome	Enrichment	FGFR2, FGFR3	4.04
38	Lacrimoauriculodentodigital syndrome 1	Enrichment	FGFR2, FGFR3	4.04
39	Tuberous sclerosis 1	Enrichment	TSC1, TSC2	4.04
40	Immunodeficiency 14a with lymphoproliferation, autosomal dominant	Enrichment	PIK3CD, PIK3R1	4.04
41	Dedifferentiated liposarcoma	Enrichment	CDK4, MDM2	4.04
42	Immunodeficiency 14	Enrichment	PIK3CD, PIK3R1	4.04
43	Well-differentiated liposarcoma	Enrichment	CDK4, MDM2	4.04
44	Langerhans cell histiocytosis	Enrichment	BRAF, MAP2K1	4.01
45	Hereditary breast carcinoma	Enrichment	AKT1, KRAS, PTEN, TP53	4.00
46	Diffuse large b-cell lymphoma	Enrichment	FOXO1, PTEN, TP53	3.83
47	Megalencephaly-capillary malformation-polymicrogyria syndrome	Enrichment	AKT3, PIK3R2	3.75
48	Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 1	Enrichment	AKT3, PIK3R2	3.75
49	Saethre-chotzen syndrome	Enrichment	FGFR2, FGFR3	3.75
50	Lung sarcomatoid carcinoma	Enrichment	KRAS, TP53	3.75
51	Tuberous sclerosis	Enrichment	TSC1, TSC2	3.75
52	Noonan syndrome with multiple lentigines	Enrichment	BRAF, RAF1	3.71
53	Hepatocellular carcinoma	Enrichment	IGF2R, MET, TP53	3.63
54	Myeloma, multiple	Enrichment	FGFR3, KRAS, PIK3R2, TP53	3.59
55	Hemifacial hyperplasia	Enrichment	FGFR2, FGFR3	3.53
56	Rhabdomyosarcoma 2	Enrichment	FOXO1, TP53	3.53
57	Acute megakaryocytic leukemia	Enrichment	PTEN, TP53	3.53
58	Primary ovarian insufficiency	Enrichment	IGF2R, KDR, NTRK1, RICTOR	3.51
59	Li-fraumeni syndrome	Enrichment	MDM2, TP53	3.35
60	Cowden syndrome 1	Enrichment	EGFR, PTEN	3.35
61	Hemangioma, capillary infantile	Enrichment	FLT4, KDR	3.35
62	46,xy disorder of sex development	Enrichment	FGFR3, INSR	3.35
63	Nevus, epidermal	Enrichment	FGFR3, KRAS	3.21
64	Multiple endocrine neoplasia, type i	Enrichment	CDKN1A, CDKN1B	3.21
65	Renal cell carcinoma, papillary, 1	Enrichment	MET, MTOR	3.21
66	Gallbladder cancer	Enrichment	KRAS, TP53	3.21
67	Overgrowth syndrome	Enrichment	MTOR, PIK3R1	3.21
68	Capillary malformation-arteriovenous malformation 1	Enrichment	KRAS, MAP2K1	3.17
69	Noonan syndrome 3	Enrichment	KRAS, RAF1	3.17
70	Breast cancer	Enrichment	AKT1, KRAS, PTEN, TP53	3.11
71	Glioma susceptibility 1	Enrichment	ERBB2, TP53	3.08
72	Melanocytic nevus syndrome, congenital	Enrichment	BRAF, RAF1	3.05
73	Cowden syndrome	Enrichment	AKT1, PTEN	2.98
74	Arteriovenous malformation	Enrichment	MAP2K1, TEK	2.94
75	Ventricular septal defect	Enrichment	BRAF, TEK	2.94
76	Autosomal non-syndromic agammaglobulinemia	Enrichment	PIK3CD, PIK3R1	2.88
77	Myopathy, x-linked, with excessive autophagy	Enrichment	MAP2K1, TEK	2.85
78	Meningioma	Enrichment	AKT1, PTEN	2.72
79	Renal cell carcinoma, nonpapillary	Enrichment	MET, MTOR	2.52
80	Hydrocephalus	Enrichment	FGFR2, PDGFRB	2.52
81	Rhabdomyosarcoma	Enrichment	PTEN, TP53	2.46
82	Hereditary breast ovarian cancer syndrome	Enrichment	KRAS, PTEN, TP53	2.46
83	Melanoma, cutaneous malignant 1	Enrichment	BRAF, CDK4	2.38
84	Dandy-walker syndrome	Enrichment	BRAF, PDGFRB	2.38
85	Craniosynostosis	Enrichment	FGFR2, FGFR3	2.27
86	Erythroleukemia, familial	Enrichment	ERBB3	2.26
87	Hypochondroplasia	Enrichment	FGFR3	2.26
88	Proteus syndrome	Enrichment	AKT1	2.26
89	Beare-stevenson cutis gyrata syndrome	Enrichment	FGFR2	2.26
90	Paget disease, extramammary	Enrichment	ERBB2	2.26
91	Osteoglophonic dysplasia	Enrichment	FGFR1	2.26
92	Thanatophoric dysplasia, type i	Enrichment	FGFR3	2.26
93	Trigonocephaly 1	Enrichment	FGFR1	2.26
94	Hypoinsulinemic hypoglycemia with hemihypertrophy	Enrichment	AKT2	2.26
95	Donohue syndrome	Enrichment	INSR	2.26
96	Oculoectodermal syndrome	Enrichment	KRAS	2.26
97	Muenke syndrome	Enrichment	FGFR3	2.26
98	Vacterl association with hydrocephalus	Enrichment	PTEN	2.26
99	Premature aging syndrome, penttinen type	Enrichment	PDGFRB	2.26
100	Hyperinsulinemic hypoglycemia, familial, 5	Enrichment	INSR	2.26
101	Pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities	Enrichment	INSR	2.26
102	Diabetes mellitus, insulin-resistant, with acanthosis nigricans	Enrichment	INSR	2.26
103	Hypereosinophilic syndrome, idiopathic	Enrichment	PDGFRA	2.26
104	Melanoma, cutaneous malignant 3	Enrichment	CDK4	2.26
105	Scaphocephaly, maxillary retrusion, and impaired intellectual development	Enrichment	FGFR2	2.26
106	Apert syndrome	Enrichment	FGFR2	2.26
107	Parkinson disease 18, autosomal dominant	Enrichment	EIF4G1	2.26
108	Myofibromatosis, infantile, 1	Enrichment	PDGFRB	2.26
109	Thanatophoric dysplasia, type ii	Enrichment	FGFR3	2.26
110	Lethal congenital contracture syndrome 2	Enrichment	ERBB3	2.26
111	Gist-plus syndrome	Enrichment	PDGFRA	2.26
112	Camptodactyly, tall stature, and hearing loss syndrome	Enrichment	FGFR3	2.26
113	Accelerated tumor formation	Enrichment	MDM2	2.26
114	Bent bone dysplasia syndrome 1	Enrichment	FGFR2	2.26
115	Visceral neuropathy, familial, 2, autosomal recessive	Enrichment	ERBB2	2.26
116	Developmental and epileptic encephalopathy 58	Enrichment	NTRK2	2.26
117	Venous malformations, multiple cutaneous and mucosal	Enrichment	TEK	2.26
118	Lessel-kubisch syndrome	Enrichment	MDM2	2.26
119	Short syndrome	Enrichment	PIK3R1	2.26
120	Bone marrow failure syndrome 5	Enrichment	TP53	2.26
121	Osteofibrous dysplasia	Enrichment	MET	2.26
122	Papilloma of choroid plexus	Enrichment	TP53	2.26
123	Basal cell carcinoma 7	Enrichment	TP53	2.26
124	Autism 19	Enrichment	EIF4E	2.26
125	Myeloid and lymphoid neoplasms associated with pdgfra rearrangement	Enrichment	PDGFRA	2.26
126	Anaplastic thyroid carcinoma	Enrichment	TP53	2.26
127	Papillary tumor of the pineal region	Enrichment	PTEN	2.26
128	Cardiofaciocutaneous syndrome 2	Enrichment	KRAS	2.26
129	Deafness, autosomal recessive 97	Enrichment	MET	2.26
130	Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 2	Enrichment	AKT3	2.26
131	Crouzon syndrome with acanthosis nigricans	Enrichment	FGFR3	2.26
132	Neuroendocrine tumor	Enrichment	CDKN1B	2.26
133	Autism 9	Enrichment	MET	2.26
134	Basal ganglia calcification, idiopathic, 4	Enrichment	PDGFRB	2.26
135	Immunodeficiency 36 with lymphoproliferation	Enrichment	PIK3R1	2.26
136	Cowden syndrome 6	Enrichment	AKT1	2.26
137	Amyotrophic lateral sclerosis 19	Enrichment	ERBB4	2.26
138	Immunodeficiency 14b, autosomal recessive	Enrichment	PIK3CD	2.26
139	Myeloid and lymphoid neoplasms associated with pdgfrb rearrangement	Enrichment	PDGFRB	2.26
140	Agammaglobulinemia 7, autosomal recessive	Enrichment	PIK3R1	2.26
141	Immunodeficiency 97 with autoinflammation	Enrichment	PIK3CG	2.26
142	Obesity, hyperphagia, and developmental delay	Enrichment	NTRK2	2.26
143	Glioma susceptibility 2	Enrichment	PTEN	2.26
144	Achondroplasia, severe, with developmental delay and acanthosis nigricans	Enrichment	FGFR3	2.26
145	Ductal carcinoma in situ	Enrichment	TP53	2.26
146	Kosaki overgrowth syndrome	Enrichment	PDGFRB	2.26
147	Hartsfield syndrome	Enrichment	FGFR1	2.26
148	Congenital heart defects, multiple types, 7	Enrichment	FLT4	2.26
149	Glaucoma 3, primary congenital, e	Enrichment	TEK	2.26
150	Ocular pterygium-digital keloid dysplasia syndrome	Enrichment	PDGFRB	2.26
151	Thyroid gland undifferentiated carcinoma	Enrichment	TP53	2.26
152	Tufted angioma of skin	Enrichment	KDR	2.26
153	Small-cell carcinoma of the ovary of hypercalcemic type	Enrichment	TP53	2.26
154	Arthrogryposis, distal, type 11	Enrichment	MET	2.26
155	Lacrimoauriculodentodigital syndrome 2	Enrichment	FGFR3	2.26
156	Bockenheimer syndrome	Enrichment	TEK	2.26
157	Capillary hemangioma	Enrichment	AKT3	2.26
158	Diffuse pediatric-type high-grade glioma, h3-wildtype and idh-wildtype	Enrichment	TP53	2.26
159	Congenital pulmonary airway malformation	Enrichment	KRAS	2.26
160	Choroid plexus cancer	Enrichment	TP53	2.26
161	Fgfr3-related chondrodysplasia	Enrichment	FGFR3	2.26
162	Camptodactyly-tall stature-scoliosis-hearing loss syndrome	Enrichment	FGFR3	2.26
163	Pleomorphic xanthoastrocytoma	Enrichment	TP53	2.26
164	Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome	Enrichment	PTEN	2.26
165	Hartsfield-bixler-demyer syndrome	Enrichment	FGFR1	2.26
166	Non-syndromic unicoronal craniosynostosis	Enrichment	FGFR2	2.26
167	Serous carcinoma of the corpus uteri	Enrichment	ERBB2	2.26
168	Akt2-related familial partial lipodystrophy	Enrichment	AKT2	2.26
169	Pallister-killian syndrome	Enrichment	ARAF	2.24
170	Immunodeficiency due to defect in mapbp-interacting protein	Enrichment	LAMTOR2	2.24
171	Noonan syndrome 5	Enrichment	RAF1	2.24
172	Melorheostosis, isolated	Enrichment	MAP2K1	2.24
173	Noonan syndrome 7	Enrichment	BRAF	2.24
174	Leopard syndrome 3	Enrichment	BRAF	2.24
175	Cardiomyopathy, dilated, 1nn	Enrichment	RAF1	2.24
176	Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 3	Enrichment	CCND2	2.24
177	Cardiofaciocutaneous syndrome 3	Enrichment	MAP2K1	2.24
178	Noonan syndrome 9	Enrichment	SOS2	2.24
179	Noonan syndrome 11	Enrichment	MRAS	2.24
180	Immunodeficiency 64 with lymphoproliferation	Enrichment	RASGRP1	2.24
181	Noonan syndrome 13	Enrichment	MAPK1	2.24
182	Immune dysregulation, autoimmunity, and autoinflammation	Enrichment	PLCG1	2.24
183	Lymphangioma	Enrichment	BRAF	2.24
184	Phace association	Enrichment	BRAF	2.24
185	Melorheostosis	Enrichment	MAP2K1	2.24
186	Leopard syndrome 2	Enrichment	RAF1	2.24
187	Cardiofaciocutaneous syndrome 4	Enrichment	MAP2K2	2.24
188	Autoinflammation, antibody deficiency, and immune dysregulation	Enrichment	PLCG2	2.24
189	Hypogonadotropic hypogonadism 18 with or without anosmia	Enrichment	IL17RD	2.24
190	Familial cold autoinflammatory syndrome 3	Enrichment	PLCG2	2.24
191	Thrombocytopenia 6	Enrichment	SRC	2.24
192	Trigonitis	Enrichment	RAF1	2.24
193	Trilateral retinoblastoma	Enrichment	RB1	2.24
194	Immunodeficiency 64	Enrichment	RASGRP1	2.24
195	Ebv-induced lymphoproliferative disease due to rasgrp1 deficiency	Enrichment	RASGRP1	2.24
196	Syringocystadenoma papilliferum	Enrichment	BRAF	2.24
197	Diamond-blackfan anemia 22	Enrichment	RPL17	2.24
198	Ganglioglioma	Enrichment	BRAF	2.24
199	Nongerminomatous germ cell tumor	Enrichment	BRAF	2.24
200	Phace syndrome	Enrichment	BRAF	2.24
201	Primary immunodeficiency syndrome due to p14 deficiency	Enrichment	LAMTOR2	2.24
202	Classic hairy cell leukemia	Enrichment	BRAF	2.24
203	Lung oat cell carcinoma	Enrichment	RB1	2.24
204	Endometrial cancer	Enrichment	FGFR2, PTEN	2.23
205	Hepatoblastoma	Enrichment	FGFR3, TP53	2.23
206	Kallmann syndrome	Enrichment	FGFR1, IL17RD	2.12
207	Pancreatic cancer	Enrichment	KRAS, TP53	2.08
208	Tetralogy of fallot	Enrichment	FLT4, KDR	2.05
209	Lymphatic malformation 1	Enrichment	FLT4	1.96
210	Burkitt lymphoma	Enrichment	MYC	1.96
211	Blue rubber bleb nevus	Enrichment	TEK	1.96
212	Myeloproliferative disorder, chronic, with eosinophilia	Enrichment	PDGFRB	1.96
213	Adrenocortical carcinoma, hereditary	Enrichment	TP53	1.96
214	Insensitivity to pain, congenital, with anhidrosis	Enrichment	NTRK1	1.96
215	Visceral neuropathy, familial, 1, autosomal recessive	Enrichment	ERBB3	1.96
216	Intracranial hypertension, idiopathic	Enrichment	FLT4	1.96
217	Hyperinsulinemic hypoglycemia, familial, 4	Enrichment	INSR	1.96
218	Aural atresia, congenital	Enrichment	FGFR2	1.96
219	Keratosis, seborrheic	Enrichment	FGFR3	1.96
220	Ras-associated autoimmune leukoproliferative disorder	Enrichment	KRAS	1.96
221	Roifman-chitayat syndrome	Enrichment	PIK3CD	1.96
222	Angioma, tufted	Enrichment	KDR	1.96
223	Lymphoma, hodgkin, classic	Enrichment	TP53	1.96
224	Multiple endocrine neoplasia, type iv	Enrichment	CDKN1B	1.96
225	Pain sensitivity quantitative trait locus 1	Enrichment	NTRK1	1.96
226	Antley-bixler syndrome without genital anomalies or disordered steroidogenesis	Enrichment	FGFR2	1.96
227	Lymphatic malformation 11	Enrichment	TIE1	1.96
228	Cebalid syndrome	Enrichment	MTOR	1.96
229	Infantile myofibromatosis	Enrichment	PDGFRB	1.96
230	Childhood hepatocellular carcinoma	Enrichment	MET	1.96
231	Senior-loken syndrome 7	Enrichment	AKT3	1.96
232	Split hand-foot malformation	Enrichment	FGFR2	1.96
233	Rosette-forming glioneuronal tumor	Enrichment	FGFR1	1.96
234	Papillary renal cell carcinoma	Enrichment	MET	1.96
235	Congenital mesoblastic nephroma	Enrichment	NTRK3	1.96
236	Congenital fibrosarcoma	Enrichment	TP53	1.96
237	Li-fraumeni syndrome 1	Enrichment	TP53	1.96
238	Sarcoma	Enrichment	TP53	1.96
239	Immune system disease	Enrichment	PIK3CD	1.96
240	Hodgkin's lymphoma	Enrichment	TP53	1.96
241	Fibrosarcoma	Enrichment	NTRK3	1.96
242	Bardet-biedl syndrome 16	Enrichment	AKT3	1.96
243	Smith-kingsmore syndrome	Enrichment	MTOR	1.96
244	Hereditary lymphedema i	Enrichment	FLT4	1.96
245	Interfrontal craniofaciosynostosis	Enrichment	FGFR1	1.96
246	Autosomal dominant nonsyndromic deafness	Enrichment	FGFR2	1.96
247	Chronic eosinophilic leukemia	Enrichment	PDGFRA	1.96
248	Vacterl with hydrocephalus	Enrichment	PTEN	1.96
249	B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormality	Enrichment	PDGFRA	1.96
250	Juvenile polyposis of infancy	Enrichment	PTEN	1.96
251	Pleomorphic rhabdomyosarcoma	Enrichment	TP53	1.96
252	Hirschsprung disease 1	Enrichment	ERBB2, ERBB3	1.95
253	Prostate cancer	Enrichment	PTEN, TP53	1.95
254	Pulmonic stenosis	Enrichment	BRAF	1.94
255	Developmental and epileptic encephalopathy 50	Enrichment	CAD	1.94
256	Chromosome 13q14 deletion syndrome	Enrichment	RB1	1.94
257	Nanophthalmos 2	Enrichment	MFRP	1.94
258	Microphthalmia, isolated 5	Enrichment	MFRP	1.94
259	Familial retinoblastoma	Enrichment	RB1	1.94
260	Tafro syndrome	Enrichment	MAP2K2	1.94
261	Non-immune hydrops fetalis	Enrichment	FLT4, KRAS	1.90
262	Achondroplasia	Enrichment	FGFR3	1.78
263	Hypogonadotropic hypogonadism 2 with or without anosmia	Enrichment	FGFR1	1.78
264	Larsen syndrome	Enrichment	FGFR3	1.78
265	Thyroid carcinoma, familial medullary	Enrichment	NTRK1	1.78
266	Polycystic kidney disease, infantile severe, with tuberous sclerosis	Enrichment	TSC2	1.78
267	Osteogenic sarcoma	Enrichment	TP53	1.78
268	Nasopharyngeal carcinoma	Enrichment	TP53	1.78
269	Congenital lipomatous overgrowth, vascular malformations, and epidermal nevi	Enrichment	PIK3R1	1.78
270	Tuberous sclerosis 2	Enrichment	TSC2	1.78
271	Chromosome 8p11 myeloproliferative syndrome	Enrichment	FGFR1	1.78
272	Neonatal nephrocutaneous inflammatory syndrome	Enrichment	EGFR	1.78
273	High-grade b-cell lymphoma double-hit/triple-hit	Enrichment	MYC	1.78
274	Atypical teratoid rhabdoid tumor	Enrichment	TP53	1.78
275	Testicular germ cell cancer	Enrichment	FGFR3	1.78
276	Anaplastic astrocytoma	Enrichment	TP53	1.78
277	Xanthinuria, type ii	Enrichment	TSC2	1.78
278	Squamous cell carcinoma	Enrichment	TP53	1.78
279	Adenocarcinoma	Enrichment	TP53	1.78
280	Laryngeal squamous cell carcinoma	Enrichment	PTEN	1.78
281	Bone osteosarcoma	Enrichment	TP53	1.78
282	Spermatocytoma	Enrichment	FGFR3	1.78
283	Growth delay due to insulin-like growth factor i resistance	Enrichment	IGF1R	1.78
284	Neonatal inflammatory skin and bowel disease	Enrichment	EGFR	1.78
285	Renal cell carcinoma	Enrichment	MET	1.78
286	Testicular cancer	Enrichment	FGFR3	1.78
287	Retinoblastoma	Enrichment	RB1	1.77
288	Ataxia-telangiectasia	Enrichment	BRAF	1.77
289	Late-onset retinal degeneration	Enrichment	MFRP	1.77
290	Woolly hair, autosomal recessive 3	Enrichment	RB1	1.77
291	Hypotrichosis 8	Enrichment	RB1	1.77
292	Tethered spinal cord syndrome	Enrichment	BRAF	1.77
293	Macrocytic anemia	Enrichment	RPL17	1.77
294	Neurodegeneration, childhood-onset, with brain atrophy	Enrichment	UBTF	1.77
295	Leukemia, acute myeloid	Enrichment	KRAS, TP53	1.69
296	Congenital nervous system abnormality	Enrichment	FGFR3, PTEN, TSC2	1.68
297	Nervous system disease	Enrichment	FGFR3, PTEN, TSC2	1.68
298	Schimmelpenning-feuerstein-mims syndrome	Enrichment	KRAS	1.66
299	Diffuse gastric and lobular breast cancer syndrome	Enrichment	KRAS	1.66
300	Small cell cancer of the lung	Enrichment	TP53	1.66
301	Thyroid cancer, nonmedullary, 1	Enrichment	TP53	1.66
302	Glaucoma 3, primary infantile, b	Enrichment	TEK	1.66
303	Barrett esophagus	Enrichment	ERBB2	1.66
304	Chronic myelogenous leukemia, bcr-abl1 positive	Enrichment	KRAS	1.66
305	Embryonal rhabdomyosarcoma	Enrichment	TP53	1.66
306	Pilocytic astrocytoma	Enrichment	KRAS	1.66
307	Non-syndromic bicoronal craniosynostosis	Enrichment	FGFR3	1.66
308	Primary hyperparathyroidism	Enrichment	CDKN1B	1.66
309	Type 2 diabetes mellitus	Enrichment	AKT2, INSR	1.65
310	Neurofibromatosis-noonan syndrome	Enrichment	MAP2K2	1.64
311	Chromosome 22q11.2 deletion syndrome, distal	Enrichment	MAPK1	1.64
312	Lynch syndrome 4	Enrichment	RB1	1.64
313	Mantle cell lymphoma	Enrichment	CCND1	1.64
314	Craniopharyngioma	Enrichment	BRAF	1.64
315	Newborn respiratory distress syndrome	Enrichment	BRAF	1.64
316	Male infertility due to gonadal dysgenesis or sperm disorder	Enrichment	SOS2	1.64
317	West syndrome	Enrichment	NTRK2, TSC2	1.61
318	Macrocephaly/autism syndrome	Enrichment	PTEN	1.56
319	Insulin-like growth factor i	Enrichment	IGF1R	1.56
320	Pre-eclampsia	Enrichment	FLT1	1.56
321	Lymphoma	Enrichment	TP53	1.56
322	Holoprosencephaly	Enrichment	FGFR1	1.56
323	Hemangioma	Enrichment	PTEN	1.56
324	Von hippel-lindau syndrome	Enrichment	CCND1	1.55
325	Rare syndromic intellectual disability	Enrichment	UBTF	1.55
326	Split-hand/foot malformation 1	Enrichment	FGFR2	1.49
327	Holoprosencephaly 1	Enrichment	FGFR1	1.49
328	Testicular germ cell tumor	Enrichment	FGFR3	1.49
329	Keratoconus	Enrichment	TSC1	1.49
330	Adrenocortical carcinoma	Enrichment	TP53	1.49
331	Wilms tumor 5	Enrichment	BRAF	1.47
332	Pancytopenia	Enrichment	RPL17	1.47
333	Esophageal cancer	Enrichment	TP53	1.42
334	Polycystic kidney disease 1 with or without polycystic liver disease	Enrichment	TSC2	1.42
335	Thyroid cancer, nonmedullary, 2	Enrichment	PTEN	1.42
336	Glaucoma 3, primary congenital, a	Enrichment	TEK	1.42
337	Gastrointestinal stromal tumor	Enrichment	PDGFRA	1.42
338	Leukemia, chronic myeloid	Enrichment	KRAS	1.42
339	Neuropathy, hereditary sensory and autonomic, type v	Enrichment	NTRK1	1.42
340	Polycystic kidney disease 1	Enrichment	TSC2	1.42
341	Essential thrombocythemia	Enrichment	TP53	1.42
342	Megacolon	Enrichment	AKT3	1.42
343	Follicular thyroid carcinoma	Enrichment	PTEN	1.42
344	B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)	Enrichment	TP53	1.42
345	Myelofibrosis	Enrichment	SRC	1.40
346	Arthrogryposis, distal, type 1a	Enrichment	MET	1.36
347	Basal ganglia calcification, idiopathic, 1	Enrichment	PDGFRB	1.36
348	Lymphoma, non-hodgkin, familial	Enrichment	TP53	1.36
349	Hypogonadotropic hypogonadism	Enrichment	FGFR1	1.31
350	Primary hyperaldosteronism	Enrichment	TP53	1.31
351	Cardiomyopathy, familial hypertrophic, 4	Enrichment	BRAF	1.30
352	Leukemia, chronic lymphocytic	Enrichment	TP53	1.27
353	Meier-gorlin syndrome 1	Enrichment	FGFR2	1.27
354	Polymicrogyria	Enrichment	AKT3	1.27
355	Melanoma	Enrichment	PTEN	1.27
356	Familial colorectal cancer	Enrichment	TP53	1.27
357	Primary bone dysplasia	Enrichment	FGFR3	1.27
358	Meningioma, familial	Enrichment	PTEN	1.23
359	Myelodysplastic syndrome	Enrichment	TP53	1.23
360	Osteochondrodysplasia	Enrichment	FGFR3	1.23
361	Uterine corpus cancer	Enrichment	PTEN	1.23
362	Nanophthalmos	Enrichment	MFRP	1.21
363	Specific learning disability	Enrichment	MAPK1	1.21
364	Septooptic dysplasia	Enrichment	FGFR1	1.19
365	Juvenile myelomonocytic leukemia	Enrichment	KRAS	1.19
366	Renal hypodysplasia/aplasia 3	Enrichment	FGFR3	1.19
367	Epicanthus	Enrichment	RPL17	1.17
368	Hypogonadotropic hypogonadism 7 with or without anosmia	Enrichment	FGFR1	1.13
369	Cleft lip/palate	Enrichment	PDGFRA	1.13
370	Dilated cardiomyopathy	Enrichment	BRAF, RAF1	1.11
371	Osteoporosis	Enrichment	SRC	1.11
372	Lynch syndrome	Enrichment	KRAS	1.10
373	Autosomal dominant polycystic kidney disease	Enrichment	TSC2	1.10
374	Kidney disease	Enrichment	TSC1	1.10
375	Rare genetic intellectual disability	Enrichment	MTOR	1.10
376	Wilms tumor 1	Enrichment	BRAF	1.08
377	Microform holoprosencephaly	Enrichment	FGFR1	1.07
378	Lobar holoprosencephaly	Enrichment	FGFR1	1.07
379	Semilobar holoprosencephaly	Enrichment	FGFR1	1.02
380	Normosmic congenital hypogonadotropic hypogonadism	Enrichment	FGFR1	1.02
381	Heart, malformation of	Enrichment	MAPK1	1.01
382	Tooth agenesis	Enrichment	FGFR1	0.94
383	Attention deficit-hyperactivity disorder	Enrichment	RPL17	0.92
384	Diamond-blackfan anemia 1	Enrichment	TP53	0.92
385	Precursor t-cell acute lymphoblastic leukemia	Enrichment	MYC	0.92
386	Autism spectrum disorder	Enrichment	PTEN, TSC2	0.91
387	Parkinson disease, late-onset	Enrichment	EIF4G1	0.90
388	Cardiomyopathy, familial hypertrophic, 1	Enrichment	RAF1	0.89
389	Hydrops fetalis, nonimmune	Enrichment	FLT4	0.87
390	Developmental and epileptic encephalopathy 1	Enrichment	CAD	0.87
391	Microcephaly	Enrichment	IGF1R, MAPK1	0.80
392	Connective tissue disease	Enrichment	FGFR3	0.79
393	Familial hypertrophic cardiomyopathy	Enrichment	RAF1	0.76
394	Diamond-blackfan anemia	Enrichment	TP53	0.74
395	Left ventricular noncompaction	Enrichment	RAF1	0.74
396	Cerebral palsy	Enrichment	PDGFRB	0.71
397	Thrombocytopenia	Enrichment	SRC	0.62
398	Autosomal dominant non-syndromic intellectual disability	Enrichment	ERBB4	0.62
399	Hypertelorism	Enrichment	FGFR2	0.60
400	Familial isolated dilated cardiomyopathy	Enrichment	RAF1	0.58
401	Undetermined early-onset epileptic encephalopathy	Enrichment	NTRK2	0.57
402	Frontotemporal dementia and/or amyotrophic lateral sclerosis 7	Enrichment	ERBB4	0.56
403	Autism	Enrichment	RPL17	0.47
404	Rare autosomal recessive non-syndromic sensorineural deafness type dfnb	Enrichment	MET	0.41
405	Hereditary retinal dystrophy	Enrichment	MFRP	0.09
406	Fundus dystrophy	Enrichment	MFRP	0.09

¹ WikiPathways

² PubChem

³ R&D Systems

⁴ Reactome

⁵ GeneGo (Thomson Reuters)

⁶ QIAGEN

⁷ PharmGKB

⁸ Cell Signaling Technology

⁹ Sino Biological

¹⁰ Tocris

¹¹ MalaCards

MAPK Signaling: Mitogens

Pathway Network for MAPK Signaling: Mitogens

Member Pathways for MAPK Signaling: Mitogens

Pathways in the MAPK Signaling: Mitogens SuperPath

Associated Genes for MAPK Signaling: Mitogens

Associated Disorders for MAPK Signaling: Mitogens

Disorders associated with MAPK Signaling: Mitogens SuperPath

STRING Interaction Network for MAPK Signaling: Mitogens

Sources for MAPK Signaling: Mitogens